Get notified when QDEL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Material Weakness (improved) — Material weakness in internal control over financial reporting has been remediated; controls now deemed effective.
- Securities Litigation (new) — Federal securities class action and derivative suits remain active; motion to dismiss filed April 2025.
QuidelOrtho Q1 revenue falls 11% on weak flu season; margin compresses 700bp
Filed May 6, 2026 · Period ending March 29, 2026 · Compared to 10-Q May 8, 2025 · ~1 min read
Key Changes
-
high
Cost of sales jumped to 57.4% of revenue from 50.4% prior year, a 700 basis point margin compression driven by higher employee compensation costs, erasing prior procurement savings.
MD&A: Cost of Sales verify on EDGAR → -
high
Operating cash flow swung from $65.6M inflow to $33.0M outflow year-over-year, driven by $91.8M net loss and $72.6M inventory build versus $53.1M prior year.
MD&A: Cash Flow verify on EDGAR → -
high
China NHSA draft IVD pricing guidelines issued March 2026 contributed to lower Labs purchase volumes; final rules unpublished and business impact not yet assessable.
MD&A: China Pricing verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FRVO 10-Q) is open in full — no account needed.
Partner
Trade QDEL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 26, 2026 12:45 AM